A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders

Susan L. Mcelroy, Mark A Frye, Lori L. Altshuler, Trisha Suppes, Gerhard Hellemann, David Black, Jim Mintz, Ralph Kupka, Willem Nolen, Gabriele S. Leverich, Kirk D. Denicoff, Robert M. Post, Paul E. Keck

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Objectives: Patients with bipolar disorder (BD) have an increased risk of obesity as well as psychotropic-associated weight gain. The objective of this study was to compare sibutramine and topiramate as adjunctive treatments for psychotropic-associated weight gain in overweight or obese outpatients with BD. Methods: In this 24-week, open-label, flexible-dose, comparison trial, 46 outpatients with bipolar disorders who had a body mass index (BMI) ≥30 kg/m2, or ≥27 kg/m2 with obesity-related comorbidities, and psychotropic-associated weight gain were randomly assigned to receive sibutramine (n=18; 5-15 mg/day) or topiramate (n=28; 25-600 mg/day). The primary outcome measure was weight loss. Secondary measures included changes in BMI, percent body weight loss, and mood symptoms. Results: Patients randomized either to sibutramine or topiramate lost comparable amounts of weight (4.1±5.7 and 2.8±3.5 kg, respectively) and displayed similar rates of weight loss (0.85 and 0.82 kg/week, respectively). However, only four (22%) patients receiving sibutramine and six (21%) patients receiving topiramate completed the 24-week trial. In addition, the attrition patterns for the two drugs were different, with patients discontinuing topiramate doing so early in treatment and patients discontinuing sibutramine doing so throughout treatment. Also, higher ratings of manic and depressive symptoms significantly increased risk for early topiramate discontinuation compared to that for sibutramine. Conclusions: Adjunctive sibutramine and topiramate may have comparable weight loss effects in overweight or obese bipolar patients with psychotropic-associated weight gain, but are each associated with similarly high discontinuation rates. In addition, they may have different attrition profiles. Compared to sibutramine, discontinuation of topiramate may be more likely to occur early in treatment and may be more dependent upon manic and depressive symptoms.

Original languageEnglish (US)
Pages (from-to)426-434
Number of pages9
JournalBipolar Disorders
Volume9
Issue number4
DOIs
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

sibutramine
Bipolar Disorder
Weight Gain
Randomized Controlled Trials
Weight Loss
Therapeutics
Body Mass Index
Outpatients
Obesity
Depression
topiramate

Keywords

  • Bipolar disorder
  • Obesity
  • Sibutramine
  • Topiramate
  • Weight gain

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Cite this

A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. / Mcelroy, Susan L.; Frye, Mark A; Altshuler, Lori L.; Suppes, Trisha; Hellemann, Gerhard; Black, David; Mintz, Jim; Kupka, Ralph; Nolen, Willem; Leverich, Gabriele S.; Denicoff, Kirk D.; Post, Robert M.; Keck, Paul E.

In: Bipolar Disorders, Vol. 9, No. 4, 06.2007, p. 426-434.

Research output: Contribution to journalArticle

Mcelroy, SL, Frye, MA, Altshuler, LL, Suppes, T, Hellemann, G, Black, D, Mintz, J, Kupka, R, Nolen, W, Leverich, GS, Denicoff, KD, Post, RM & Keck, PE 2007, 'A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders', Bipolar Disorders, vol. 9, no. 4, pp. 426-434. https://doi.org/10.1111/j.1399-5618.2007.00488.x
Mcelroy, Susan L. ; Frye, Mark A ; Altshuler, Lori L. ; Suppes, Trisha ; Hellemann, Gerhard ; Black, David ; Mintz, Jim ; Kupka, Ralph ; Nolen, Willem ; Leverich, Gabriele S. ; Denicoff, Kirk D. ; Post, Robert M. ; Keck, Paul E. / A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. In: Bipolar Disorders. 2007 ; Vol. 9, No. 4. pp. 426-434.
@article{a441480afc7d4e6b86213097433a9221,
title = "A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders",
abstract = "Objectives: Patients with bipolar disorder (BD) have an increased risk of obesity as well as psychotropic-associated weight gain. The objective of this study was to compare sibutramine and topiramate as adjunctive treatments for psychotropic-associated weight gain in overweight or obese outpatients with BD. Methods: In this 24-week, open-label, flexible-dose, comparison trial, 46 outpatients with bipolar disorders who had a body mass index (BMI) ≥30 kg/m2, or ≥27 kg/m2 with obesity-related comorbidities, and psychotropic-associated weight gain were randomly assigned to receive sibutramine (n=18; 5-15 mg/day) or topiramate (n=28; 25-600 mg/day). The primary outcome measure was weight loss. Secondary measures included changes in BMI, percent body weight loss, and mood symptoms. Results: Patients randomized either to sibutramine or topiramate lost comparable amounts of weight (4.1±5.7 and 2.8±3.5 kg, respectively) and displayed similar rates of weight loss (0.85 and 0.82 kg/week, respectively). However, only four (22{\%}) patients receiving sibutramine and six (21{\%}) patients receiving topiramate completed the 24-week trial. In addition, the attrition patterns for the two drugs were different, with patients discontinuing topiramate doing so early in treatment and patients discontinuing sibutramine doing so throughout treatment. Also, higher ratings of manic and depressive symptoms significantly increased risk for early topiramate discontinuation compared to that for sibutramine. Conclusions: Adjunctive sibutramine and topiramate may have comparable weight loss effects in overweight or obese bipolar patients with psychotropic-associated weight gain, but are each associated with similarly high discontinuation rates. In addition, they may have different attrition profiles. Compared to sibutramine, discontinuation of topiramate may be more likely to occur early in treatment and may be more dependent upon manic and depressive symptoms.",
keywords = "Bipolar disorder, Obesity, Sibutramine, Topiramate, Weight gain",
author = "Mcelroy, {Susan L.} and Frye, {Mark A} and Altshuler, {Lori L.} and Trisha Suppes and Gerhard Hellemann and David Black and Jim Mintz and Ralph Kupka and Willem Nolen and Leverich, {Gabriele S.} and Denicoff, {Kirk D.} and Post, {Robert M.} and Keck, {Paul E.}",
year = "2007",
month = "6",
doi = "10.1111/j.1399-5618.2007.00488.x",
language = "English (US)",
volume = "9",
pages = "426--434",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Blackwell Munksgaard",
number = "4",

}

TY - JOUR

T1 - A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders

AU - Mcelroy, Susan L.

AU - Frye, Mark A

AU - Altshuler, Lori L.

AU - Suppes, Trisha

AU - Hellemann, Gerhard

AU - Black, David

AU - Mintz, Jim

AU - Kupka, Ralph

AU - Nolen, Willem

AU - Leverich, Gabriele S.

AU - Denicoff, Kirk D.

AU - Post, Robert M.

AU - Keck, Paul E.

PY - 2007/6

Y1 - 2007/6

N2 - Objectives: Patients with bipolar disorder (BD) have an increased risk of obesity as well as psychotropic-associated weight gain. The objective of this study was to compare sibutramine and topiramate as adjunctive treatments for psychotropic-associated weight gain in overweight or obese outpatients with BD. Methods: In this 24-week, open-label, flexible-dose, comparison trial, 46 outpatients with bipolar disorders who had a body mass index (BMI) ≥30 kg/m2, or ≥27 kg/m2 with obesity-related comorbidities, and psychotropic-associated weight gain were randomly assigned to receive sibutramine (n=18; 5-15 mg/day) or topiramate (n=28; 25-600 mg/day). The primary outcome measure was weight loss. Secondary measures included changes in BMI, percent body weight loss, and mood symptoms. Results: Patients randomized either to sibutramine or topiramate lost comparable amounts of weight (4.1±5.7 and 2.8±3.5 kg, respectively) and displayed similar rates of weight loss (0.85 and 0.82 kg/week, respectively). However, only four (22%) patients receiving sibutramine and six (21%) patients receiving topiramate completed the 24-week trial. In addition, the attrition patterns for the two drugs were different, with patients discontinuing topiramate doing so early in treatment and patients discontinuing sibutramine doing so throughout treatment. Also, higher ratings of manic and depressive symptoms significantly increased risk for early topiramate discontinuation compared to that for sibutramine. Conclusions: Adjunctive sibutramine and topiramate may have comparable weight loss effects in overweight or obese bipolar patients with psychotropic-associated weight gain, but are each associated with similarly high discontinuation rates. In addition, they may have different attrition profiles. Compared to sibutramine, discontinuation of topiramate may be more likely to occur early in treatment and may be more dependent upon manic and depressive symptoms.

AB - Objectives: Patients with bipolar disorder (BD) have an increased risk of obesity as well as psychotropic-associated weight gain. The objective of this study was to compare sibutramine and topiramate as adjunctive treatments for psychotropic-associated weight gain in overweight or obese outpatients with BD. Methods: In this 24-week, open-label, flexible-dose, comparison trial, 46 outpatients with bipolar disorders who had a body mass index (BMI) ≥30 kg/m2, or ≥27 kg/m2 with obesity-related comorbidities, and psychotropic-associated weight gain were randomly assigned to receive sibutramine (n=18; 5-15 mg/day) or topiramate (n=28; 25-600 mg/day). The primary outcome measure was weight loss. Secondary measures included changes in BMI, percent body weight loss, and mood symptoms. Results: Patients randomized either to sibutramine or topiramate lost comparable amounts of weight (4.1±5.7 and 2.8±3.5 kg, respectively) and displayed similar rates of weight loss (0.85 and 0.82 kg/week, respectively). However, only four (22%) patients receiving sibutramine and six (21%) patients receiving topiramate completed the 24-week trial. In addition, the attrition patterns for the two drugs were different, with patients discontinuing topiramate doing so early in treatment and patients discontinuing sibutramine doing so throughout treatment. Also, higher ratings of manic and depressive symptoms significantly increased risk for early topiramate discontinuation compared to that for sibutramine. Conclusions: Adjunctive sibutramine and topiramate may have comparable weight loss effects in overweight or obese bipolar patients with psychotropic-associated weight gain, but are each associated with similarly high discontinuation rates. In addition, they may have different attrition profiles. Compared to sibutramine, discontinuation of topiramate may be more likely to occur early in treatment and may be more dependent upon manic and depressive symptoms.

KW - Bipolar disorder

KW - Obesity

KW - Sibutramine

KW - Topiramate

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=34249863363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249863363&partnerID=8YFLogxK

U2 - 10.1111/j.1399-5618.2007.00488.x

DO - 10.1111/j.1399-5618.2007.00488.x

M3 - Article

C2 - 17547588

AN - SCOPUS:34249863363

VL - 9

SP - 426

EP - 434

JO - Bipolar Disorders

JF - Bipolar Disorders

SN - 1398-5647

IS - 4

ER -